US76155X1000

Plenary Presentation at EORTC-NCI-AACR 32nd Symposium on Molecular Targets and Cancer Therapeutics Describes Encouraging Tolerability and Exposure Profiles for RMC-4630

Study Findings Selected for Oral Presentation in Plenary Session at EORTC-NCI-AACR 32nd Symposium on Molecular Targets and Cancer Therapeutics REDWOOD

Presentation at 2nd Annual RAS-Targeted Drug Development Conference Highlights First Publicly Reported Data for Inhibitors of Notorious Cancer Protein KRASG12D(ON)

Presentation at 2nd Annual RAS-Targeted Drug Development Conference Highlights First Publicly Reported Data for Inhibitors of Notorious Cancer Protein KRASG12D(ON)

Underwriters’ Full Exercise of Option Brings Gross Proceeds to $179.4 Million REDWOOD CITY, Calif., July 13, 2020 (GLOBE NEWSWIRE) —

Newly Discovered Natural Product and Designed Analogues Bind to Human Protein that is Exploited by the SARS-CoV-2 Virus REDWOOD CITY,

REDWOOD CITY, Calif., June 22, 2020 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on